{"title":"Effect of actinomycin D on prostaglandin synthesis by and output from the guinea-pig uterus","authors":"N.L. Poyser, S.C. Riley","doi":"10.1016/0262-1746(87)90160-0","DOIUrl":null,"url":null,"abstract":"<div><p>The intra-uterine administration of actinomycin D on Day 10 reduced the output of prostaglandin (PG) F<sub>2α</sub> (the major PG released) from the Day 15 guinea-pig uterus <span><math><mtext>in vitro</mtext></math></span> by 80 to 85%. PGE<sub>2</sub> output was reduced by 50%, while 6-keto-PGF<sub>1α</sub> output was unaffected. Plasma progesterone levels were high (3 to 15 ng/ml) on Day 15 due to the reduction in uterine PGF<sub>2α</sub> output. Endometrial PGF<sub>2α</sub> synthesizing capacity was reduced by 50% by actinomycin D treatment, while endometrial PGE<sub>2</sub> and 6-keto-PGF<sub>1α</sub> synthesizing capacities were unaffected. Oestradiol treatment <span><math><mtext>in vivo</mtext></math></span> did not reverse the inhibitory effects of actinomycin D on uterine PG production.A23187 increased uterine PGF<sub>2α</sub>, 6-keto-PGF<sub>1α</sub> and PGE<sub>2</sub> outputs irrespective of treatment, indicating that substrate supply was always rate limiting. Actinomycin D inhibited the uterotrophic action of oestradiol indicating that fresh protein synthesis had been inhibited. Overall, this study suggests that increased protein synthesis is involved in stimulating endometrial PGF<sub>2α</sub> synthesis and release.Previous studies have shown that increases in enzyme activities induced by oestradiol are only secondary events in the stimulation of endometrial PGF<sub>2α</sub> production. We propose that oestradiol induces the synthesis of a protein (‘lipostimulin’) which, acting on a progesterone-primed uterus, “switches on” endometrial PGF<sub>2α</sub> synthesis and release by causing the activation of endometrial phospholipase A<sub>2</sub>.</p></div>","PeriodicalId":20720,"journal":{"name":"Prostaglandins, leukotrienes, and medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1987-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0262-1746(87)90160-0","citationCount":"10","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prostaglandins, leukotrienes, and medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/0262174687901600","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 10
Abstract
The intra-uterine administration of actinomycin D on Day 10 reduced the output of prostaglandin (PG) F2α (the major PG released) from the Day 15 guinea-pig uterus by 80 to 85%. PGE2 output was reduced by 50%, while 6-keto-PGF1α output was unaffected. Plasma progesterone levels were high (3 to 15 ng/ml) on Day 15 due to the reduction in uterine PGF2α output. Endometrial PGF2α synthesizing capacity was reduced by 50% by actinomycin D treatment, while endometrial PGE2 and 6-keto-PGF1α synthesizing capacities were unaffected. Oestradiol treatment did not reverse the inhibitory effects of actinomycin D on uterine PG production.A23187 increased uterine PGF2α, 6-keto-PGF1α and PGE2 outputs irrespective of treatment, indicating that substrate supply was always rate limiting. Actinomycin D inhibited the uterotrophic action of oestradiol indicating that fresh protein synthesis had been inhibited. Overall, this study suggests that increased protein synthesis is involved in stimulating endometrial PGF2α synthesis and release.Previous studies have shown that increases in enzyme activities induced by oestradiol are only secondary events in the stimulation of endometrial PGF2α production. We propose that oestradiol induces the synthesis of a protein (‘lipostimulin’) which, acting on a progesterone-primed uterus, “switches on” endometrial PGF2α synthesis and release by causing the activation of endometrial phospholipase A2.